Latest news and deals relating to the Auspex
Identify new drug targets and therapeutic classes in the Auspex
introduced the world's first Network Attached Storage (NAS) server shortly after its founding in 1987, creating a new breed of storage appliance offering significant performance and administrative benefits over general-purpose file servers.
did not initially offer native support for Windows 2000 Active Directory, we originally moved data from only 10 of the 100 direct attached storage devices in question.
is also exploiting its deuterium chemistry approach to optimize drugs in several additional therapeutic areas.
Enterprises today are seeking better utilization of their existing hardware and people resources, and the Auspex
controller is an example of a product that offers both," said James V.
Our NS3000 product family has been engineered to meet the diverse storage needs of different enterprises as well as to move toward a universal storage management solution that overcomes the inefficiencies and extra expense of today's vendor-specific storage strategies," said Mike Worhach, President of Auspex
Enterprise storage solutions provider Auspex
Systems Inc has announced three new additions to its NS3000 storage appliance family.
has granted the underwriters a 30-day option to purchase up to an aggregate of 1,050,000 additional shares of common stock at the initial public offering price to cover any over-allotments.
The California-based storage solutions provider Auspex
Systems Ltd and the UK systems management tools supplier Essential Computing Ltd have joined forces to deliver new e-mail archiving solutions.
Pharmaceuticals, a developer of next-generation medicines through the targeted deuteration of clinically validated drugs, today announced three key management hires.
An agreement has been formed between Network Attached Storage solutions provider Auspex
Systems and EDUCOM TS, a software development firm.
Pharmaceuticals, a clinical stage company developing next-generation medicines with improved safety and performance through the targeted deuteration of clinically validated drugs, today announced the appointment of Michael Grey as President and Chief Executive Officer and R.
Systems Inc has added an option that enables customers to apply for lease financing for its enterprise file servers directly from the Auspex
Pharmaceuticals, a developer of next-generation medicines with improved safety and performance through the targeted deuteration of clinically validated drugs, today announced positive results from its Phase 1 clinical trial evaluating SD-254, a Selective Serotinin-Norepinephrine Reuptake Inhibitor (SNRI).